

NONTECHNICAL ABSTRACT

No consistently effective therapy exists for metastatic cancer in adults. The transfer (by injection into the tumor) of the naturally occurring gene for human interleukin-12 (IL-12) into a growing mouse tumor led to regression of the mouse tumor.

This proposed phase I trial is designed to study the safety and toxicity of this gene delivery approach. The antitumor response induced by this strategy will also be studied. Patients with cancer underlying their skin will be treated with the IL-12 gene to the tumor site. Two lengths of treatment will be tested in this study.